生物相似白細胞介素市場規模、佔有率和成長分析：按分子類型、適應症、給藥途徑、最終用戶、患者類型、分銷管道和地區分類－2026-2033年產業預測

2024 年全球生物相似白細胞介素市場價值為 23 億美元，預計到 2025 年將成長至 27.2 億美元，到 2033 年將成長至 105.2 億美元，在預測期（2026-2033 年）內複合年成長率為 18.4%。

全球生物相似藥白細胞介素市場涵蓋了針對自體免疫、腫瘤和發炎性疾病的取得專利的白細胞介素療法的生物類似替代品。該市場透過降低藥品成本和提高患者獲得生物製藥的途徑，帶來了顯著的益處。該領域的發展正在推動研發投入的增加和成本的降低，尤其在歐洲的早期應用方面表現得更為明顯。監管協調正在促進產品進入各個地區，並簡化上市流程。在支付方壓力日益增大的情況下，醫療服務提供者正擴大用生物相似藥取代原廠藥，從而提高成本效益。此外，人工智慧驅動的分析正在透過數據整合來最佳化決策、實現監管流程自動化並提高供應鏈的應對力，從而變革整個行業，進而加速市場成長並改善患者獲得藥物的機會。

全球生物相似藥白細胞介素市場成長要素

隨著原廠生物製藥－白細胞介素療法的專利即將到期，生物相似藥迎來了進入市場的重要機會。專利到期後，企業將能夠在不侵犯智慧財產權的情況下開發等效生物相似藥，從而刺激該領域的投資。這種情況將降低市場進入門檻，促進價格競爭，使這些重要的療法更容易被患者獲得，並有助於醫療保健系統的永續性。因此，新型白細胞介素生物白細胞介素的推出將加速市場成長，促進跨治療領域的多元化發展，推動製藥公司持續創新，並豐富全球患者的治療選擇。

全球生物相似藥白細胞介素市場的限制因素

全球生物相似藥白細胞介素市場面臨許多挑戰，主要原因是不同監管機構的核准流程各不相同。每個監管機構都要求提交各自的資料包、臨床等效性研究和生產驗證，這使得情況變得非常複雜。因此，旨在進入多區域市場的公司可能面臨更長的研發週期和更高的資源投入。為了滿足各監管機構對免疫抗原性評估和藥物動力學等效性的不同要求，通常需要重複申請和進行額外的調查，從而加重監管負擔。這種複雜性可能導致一些公司在推進生物相似藥計畫時猶豫不決，最終減緩市場成長並增加製造商的合規成本。

全球生物相似藥白細胞介素市場趨勢

全球生物相似藥白細胞介素市場正經歷顯著的轉變，其發展方向是將白細胞介素生物類似藥整合到腫瘤和自體免疫疾病的治療體系中。這一趨勢的驅動力在於對成本效益的需求，以及支持其療效和安全性的臨床證據的不斷積累，使其成為醫療服務提供者和保險公司的理想選擇。為此，生產商正不斷調整其研發策略，以應對新的治療適應症，加強與學術機構的合作，並積極適應醫保報銷環境。因此，生物相似藥白細胞介素正日益被公認為現代免疫療法方案的重要組成部分，在提高患者用藥可及性的同時，也維持了治療效果。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球生物相似藥白細胞介素市場規模：依分子類型分類

• 白細胞介素-2生物類似藥
• 白細胞介素-6生物類似藥
• 白細胞介素-17生物類似藥
• 其他

全球生物相似藥白細胞介素市場規模：依適應症分類

• 自體免疫疾病
• 腫瘤學
• 發炎性疾病
• 其他

全球生物相似藥白細胞介素市場規模：依給藥途徑分類

• 靜脈注射
• 皮下注射
• 其他

全球生物相似藥白細胞介素市場規模：依最終用戶分類

• 醫院
• 專科診所
• 靜脈輸液中心
• 其他

全球生物相似藥白細胞介素市場規模：依病患類型分類

• 成年患者
• 兒童患者

全球生物相似藥白細胞介素市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 專科藥房
• 其他

全球生物相似藥白細胞介素市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Sandoz Group AG
• Celltrion, Inc.
• Samsung Bioepis Co., Ltd.
• Amgen Inc.
• Biocon Biologics Limited
• Fresenius Kabi AG
• Teva Pharmaceutical Industries Ltd.
• Alvotech SA
• STADA Arzneimittel AG
• Viatris Inc.
• Dr. Reddy's Laboratories Ltd.
• Intas Pharmaceuticals Ltd.
• Shanghai Henlius Biotech, Inc.
• NeuClone Pty Ltd.
• Bio-Thera Solutions Ltd.
• Coherus BioSciences, Inc.
• AryoGen Pharmed
• Reliance Life Sciences Pvt. Ltd.
• mAbxience Holding SL
• CinnaGen Co.

結論與建議

Global Biosimilar Interleukins Market size was valued at USD 2.3 Billion in 2024 and is poised to grow from USD 2.72 Billion in 2025 to USD 10.52 Billion by 2033, growing at a CAGR of 18.4% during the forecast period (2026-2033).

The global biosimilar interleukin market encompasses biologically similar alternatives to proprietary interleukin therapies, targeting autoimmune diseases, oncology, and inflammatory disorders. This market offers significant advantages by reducing drug costs and enhancing patient access to biologics. Evolution in this sector has led to increased R&D investments and cost savings, particularly observed in early European adoption practices. Regulatory harmonization facilitates entry into various regions, streamlining the path to market. As payer pressures increase, healthcare providers are increasingly substituting originator therapies with biosimilars, driving cost efficiency. Additionally, AI-driven analytics are transforming the landscape by optimizing decision-making through data integration, automating regulatory processes, and enhancing supply chain responsiveness, thereby accelerating market growth and improving access for patients.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biosimilar Interleukins market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biosimilar Interleukins Market Segments Analysis

Global biosimilar interleukins market is segmented by molecule type, indication, route of administration, end user, patient type, distribution channel and region. Based on molecule type, no specific sub-segments were identified. Based on indication, no specific sub-segments were identified. Based on route of administration, no specific sub-segments were identified. Based on end user, no specific sub-segments were identified. Based on patient type, no specific sub-segments were identified. Based on distribution channel, no specific sub-segments were identified. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Biosimilar Interleukins Market

The upcoming expiration of patents for original biologic interleukin therapies opens significant opportunities for biosimilar products to enter the market. As patents expire, companies can create comparable biosimilars without violating intellectual property rights, fueling investment in this sector. This scenario decreases barriers to entry and promotes competitive pricing, enhancing patient access to these critical therapies and contributing to the sustainability of healthcare systems. As a result, the introduction of new biosimilar interleukins accelerates market growth and diversification across various therapeutic areas, driving continuous innovation among pharmaceutical companies and enriching treatment options for patients worldwide.

Restraints in the Global Biosimilar Interleukins Market

The global biosimilar interleukins market faces significant challenges due to the varying approval pathways established by different regulatory agencies. Each agency mandates unique data packages, clinical comparability studies, and manufacturing validations, creating a complex landscape that can prolong development timelines and increase resource investments for companies aiming for multi-regional market access. Navigating diverse expectations related to immunogenicity assessments and pharmacokinetic equivalence often results in repeated submissions and further investigations, adding to the regulatory burden. This complexity may discourage some companies from pursuing biosimilar projects, ultimately slowing the market's growth and raising compliance costs for manufacturers.

Market Trends of the Global Biosimilar Interleukins Market

The Global Biosimilar Interleukins market is experiencing a significant shift towards the integration of interleukin-based biosimilars within oncology and autoimmune treatment frameworks. This trend is propelled by the necessity for cost-efficiency and a growing body of clinical evidence supporting their efficacy and safety profiles, making them attractive alternatives for healthcare providers and payers. In response, manufacturers are evolving their development strategies to address new therapeutic indications, fostering partnerships with academic institutions, and proactively navigating reimbursement landscapes. As a result, biosimilar interleukins are increasingly being recognized as essential elements of modern immunotherapy regimens, enhancing patient accessibility while maintaining therapeutic effectiveness.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Biosimilar Interleukins Market Size by Molecule Type & CAGR (2026-2033)

• Market Overview
• Interleukin-2 Biosimilars
• Interleukin-6 Biosimilars
• Interleukin-17 Biosimilars
• Others

Global Biosimilar Interleukins Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Autoimmune Disorders
• Oncology
• Inflammatory Disorders
• Others

Global Biosimilar Interleukins Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous Administration
• Subcutaneous Administration
• Others

Global Biosimilar Interleukins Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Infusion Centers
• Others

Global Biosimilar Interleukins Market Size by Patient Type & CAGR (2026-2033)

• Market Overview
• Adult Patients
• Pediatric Patients

Global Biosimilar Interleukins Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Others

Global Biosimilar Interleukins Market Size & CAGR (2026-2033)

• North America (Molecule Type, Indication, Route of Administration, End User, Patient Type, Distribution Channel)
  • US
  • Canada
• Europe (Molecule Type, Indication, Route of Administration, End User, Patient Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Molecule Type, Indication, Route of Administration, End User, Patient Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Molecule Type, Indication, Route of Administration, End User, Patient Type, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Molecule Type, Indication, Route of Administration, End User, Patient Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Sandoz Group AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Biologics Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alvotech S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• STADA Arzneimittel AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Henlius Biotech, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeuClone Pty Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Thera Solutions Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus BioSciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AryoGen Pharmed
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reliance Life Sciences Pvt. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• mAbxience Holding S.L.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CinnaGen Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations